476 related articles for article (PubMed ID: 9129041)
41. The design of selective and non-selective combination therapy for acute promyelocytic leukemia.
Jing Y; Waxman S
Curr Top Microbiol Immunol; 2007; 313():245-69. PubMed ID: 17217047
[TBL] [Abstract][Full Text] [Related]
42. [Double effects of arsenic trioxide (As2O3) on acute promyelocytic leukemic cell line].
Tang W; Chen G; Shi G
Zhonghua Yi Xue Za Zhi; 1997 Jul; 77(7):509-12. PubMed ID: 9772451
[TBL] [Abstract][Full Text] [Related]
43. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
Giannì M; de Thé H
Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879
[TBL] [Abstract][Full Text] [Related]
44. Long-term survey of outcome in acute promyelocytic leukemia.
Hu J; Shen Z; Sun H; Wu W; Li X; Sun G; Wang Z
Chin Med J (Engl); 2000 Feb; 113(2):107-10. PubMed ID: 11775530
[TBL] [Abstract][Full Text] [Related]
45. [In vitro study on arsenic trioxide-inducing apoptosis in primary acute promyelocytic leukemie cells].
Tang W; Chen G; Shen Z; Chen L; Shi X; Jia P; Shi G; Ni J; Chen S; Wang Z
Zhonghua Xue Ye Xue Za Zhi; 1997 Dec; 18(12):623-6. PubMed ID: 15625759
[TBL] [Abstract][Full Text] [Related]
46. Phenylarsine oxide (PAO) more intensely induces apoptosis in acute promyelocytic leukemia and As2O3-resistant APL cell lines than As2O3 by activating the mitochondrial pathway.
Sahara N; Takeshita A; Kobayashi M; Shigeno K; Nakamura S; Shinjo K; Naito K; Maekawa M; Horii T; Ohnishi K; Kitamura K; Naoe T; Hayash H; Ohno R
Leuk Lymphoma; 2004 May; 45(5):987-95. PubMed ID: 15291359
[TBL] [Abstract][Full Text] [Related]
47. Metabolism of arsenic trioxide in acute promyelocytic leukemia cells.
Khaleghian A; Ghaffari SH; Ahmadian S; Alimoghaddam K; Ghavamzadeh A
J Cell Biochem; 2014 Oct; 115(10):1729-39. PubMed ID: 24819152
[TBL] [Abstract][Full Text] [Related]
48. In vitro exposure of acute promyelocytic leukemia cells to arsenic trioxide (As2O3) induces the solitary expression of CD66c (NCA-50/90), a member of the CEA family.
Di Noto R; Boccuni P; Costantini S; Dello Russo A; Lo Pardo C; Copia C; Annunziata M; Cimino R; Ferrara F; Del Vecchio L
Tissue Antigens; 1999 Dec; 54(6):597-602. PubMed ID: 10674975
[TBL] [Abstract][Full Text] [Related]
49. Successful treatment of all-trans retinoic acid resistant and chemotherapy naïve acute promyelocytic patients with arsenic trioxide--two case reports.
Lin CP; Huang MJ; Chang IY; Lin WY
Leuk Lymphoma; 2000 Jun; 38(1-2):191-4. PubMed ID: 10811462
[TBL] [Abstract][Full Text] [Related]
50. [Basic and clinical studies of the gene product-targeting therapy based on leukemogenesis--editorial].
Chen SJ; Chen LJ; Zhou GB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Feb; 13(1):1-8. PubMed ID: 15748426
[TBL] [Abstract][Full Text] [Related]
51. Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients.
Rousselot P; Labaume S; Marolleau JP; Larghero J; Noguera MH; Brouet JC; Fermand JP
Cancer Res; 1999 Mar; 59(5):1041-8. PubMed ID: 10070961
[TBL] [Abstract][Full Text] [Related]
52. Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.
Koken MH; Daniel MT; Gianni M; Zelent A; Licht J; Buzyn A; Minard P; Degos L; Varet B; de Thé H
Oncogene; 1999 Jan; 18(4):1113-8. PubMed ID: 10023688
[TBL] [Abstract][Full Text] [Related]
53. Dual effects of arsenic trioxide (As2O3) on non-acute promyelocytic leukaemia myeloid cell lines: induction of apoptosis and inhibition of proliferation.
Rojewski MT; Baldus C; Knauf W; Thiel E; Schrezenmeier H
Br J Haematol; 2002 Mar; 116(3):555-63. PubMed ID: 11849211
[TBL] [Abstract][Full Text] [Related]
54. MicroRNAs contribute to promyelocyte apoptosis in As2O3-treated APL cells.
Liang H; Li X; Wang L; Yu S; Xu Z; Gu Y; Pan Z; Li T; Hu M; Cui H; Liu X; Zhang Y; Xu C; Guo R; Lu Y; Yang B; Shan H
Cell Physiol Biochem; 2013; 32(6):1818-29. PubMed ID: 24356076
[TBL] [Abstract][Full Text] [Related]
55. [Effects of all-trans retinoic acid, arsenic trioxide and daunorubicin on tissue factor expression in NB4 cells].
Guo W; Zhu J; Wang H
Zhonghua Xue Ye Xue Za Zhi; 1999 Sep; 20(9):453-5. PubMed ID: 11721405
[TBL] [Abstract][Full Text] [Related]
56. Role of GSTP1-1 in mediating the effect of As2O3 in the Acute Promyelocytic Leukemia cell line NB4.
Bernardini S; Nuccetelli M; Noguera NI; Bellincampi L; Lunghi P; Bonati A; Mann K; Miller WH; Federici G; Lo Coco F
Ann Hematol; 2006 Oct; 85(10):681-7. PubMed ID: 16733740
[TBL] [Abstract][Full Text] [Related]
57. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
Zhu G
Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
[TBL] [Abstract][Full Text] [Related]
58. Histone deacetylase inhibitor but not arsenic trioxide differentiates acute promyelocytic leukaemia cells with t(11;17) in combination with all-trans retinoic acid.
Kitamura K; Hoshi S; Koike M; Kiyoi H; Saito H; Naoe T
Br J Haematol; 2000 Mar; 108(4):696-702. PubMed ID: 10792271
[TBL] [Abstract][Full Text] [Related]
59. [Detection and clinical significance of PML protein expression of acute promyelocytic leukemia cells].
Song M; Wu X; Zhang M; He P
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Jul; 33(7):971-976. PubMed ID: 28712407
[TBL] [Abstract][Full Text] [Related]
60. Arsenic trioxide therapy in acute promyelocytic leukemia and beyond: from bench to bedside.
Rojewski MT; Körper S; Schrezenmeier H
Leuk Lymphoma; 2004 Dec; 45(12):2387-401. PubMed ID: 15621751
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
